LEADER 04937nam 2201333z- 450 001 9910557666403321 005 20231214133700.0 035 $a(CKB)5400000000044842 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/76871 035 $a(EXLCZ)995400000000044842 100 $a20202201d2021 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aDrug-Drug Interactions 210 $aBasel, Switzerland$cMDPI - Multidisciplinary Digital Publishing Institute$d2021 215 $a1 electronic resource (242 p.) 311 $a3-0365-2035-X 311 $a3-0365-2036-8 330 $aDrug?drug interactions (DDIs) cause a drug to affect other drugs, leading to reduced drug efficacy or increased toxicity of the affected drug. Some well-known interactions are known to be the cause of adverse drug reactions (ADRs) that are life threatening to the patient. Traditionally, DDI have been evaluated around the selective action of drugs on specific CYP enzymes. The interaction of drugs with CYP remains very important in drug interactions but, recently, other important mechanisms have also been studied as contributing to drug interaction including transport- or UDP-glucuronyltransferase as a Phase II reaction-mediated DDI. In addition, novel mechanisms of regulating DDIs can also be suggested. In the case of the substance targeted for interaction, not only the DDIs but also the herb?drug or food?drug interactions have been reported to be clinically relevant in terms of adverse side effects. Reporting examples of drug interactions on a marketed drug or studies on new mechanisms will be very helpful for preventing the side effects of the patient taking these drugs. This Special Issue aims to highlight current progress in understanding both the clinical and nonclinical interactions of commercial drugs and the elucidation of the mechanisms of drug interactions. 606 $aResearch & information: general$2bicssc 606 $aBiology, life sciences$2bicssc 610 $atadalafil 610 $aticagrelor 610 $adrug-drug interaction 610 $apharmacokinetics 610 $aplasma concentration 610 $aCYP3A4 610 $aLoxoprofen 610 $aCYP3A 610 $aDexamethasone 610 $aKetoconazole 610 $aCYP2D6 610 $aO-desmethyltramadol 610 $aphysiologically-based pharmacokinetics 610 $atramadol 610 $a(?)-sophoranone 610 $aCYP2C9 610 $apotent inhibition 610 $ain vitro 610 $ain vivo 610 $adrug interaction 610 $alow permeability 610 $ahigh plasma protein binding 610 $abiflavonoid 610 $acytochrome P450 610 $adrug interactions 610 $aselamariscina A 610 $auridine 5?-diphosphoglucuronosyl transferase 610 $atissue-specific 610 $asystemic exposure 610 $aP-glycoprotein (P-gp) 610 $aorganic anion transporting polypeptide 1A2 (OATP1A2) 610 $aRumex acetosa 610 $afexofenadine 610 $achronic kidney disease 610 $adrug?drug interactions 610 $apolypharmacy 610 $aadverse drug reactions 610 $aLexicomp 610 $asubset analysis 610 $asignal detection algorithms 610 $aspontaneous reporting systems 610 $amechanism-based inhibition 610 $acompetitive inhibition 610 $anon-competitive inhibition 610 $asubstrate 610 $ainhibitor 610 $acytochromes P450 610 $aOATP1B1 610 $aOATP1B3 610 $atyrosine kinase inhibitors 610 $adrug-drug interactions 610 $amigraine 610 $alasmiditan 610 $agepants 610 $amonoclonal antibodies 610 $aCYP1A1 610 $aCYP1A2 610 $adrug?drug interaction 610 $aexpression 610 $ametabolism 610 $aregulation 610 $adrug transporter 610 $aubiquitination 610 $aixazomib 610 $aDDI 610 $acomputational prediction 610 $ain silico 610 $aQSAR 610 $adrug metabolism 610 $aADME 610 $aCYP 610 $ametabolic DDI 610 $aP450 610 $a1A2 610 $a2B6 610 $a2C19 610 $a2C8 610 $a2C9 610 $a2D6 610 $a3A4 615 7$aResearch & information: general 615 7$aBiology, life sciences 700 $aKim$b Dong Hyun$4edt$01304704 702 $aLee$b Sangkyu$4edt 702 $aKim$b Dong Hyun$4oth 702 $aLee$b Sangkyu$4oth 906 $aBOOK 912 $a9910557666403321 996 $aDrug-Drug Interactions$93027633 997 $aUNINA